Tarsus Pharmaceuticals, Inc. TARS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| License fees and collaboration revenue | $16.67M— | $0-100% | $0-100% | $0-100% | $0-100% | |
| Product sales, net | $518.41M+122% | $451.36M+151% | $366.1M+189% | $295.52M+268% | $233.67M+492% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Tarsus Pharmaceuticals, Inc. break its business down?
- Tarsus Pharmaceuticals, Inc. (TARS) reports total revenues by product across 2 parts — License fees and collaboration revenue and Product sales, net. Each is extracted from the segment footnotes and tracked over time.
- Where does Tarsus Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Tarsus Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
